Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles.
New effective antimalarial agents are urgently needed due to increasing drug resistance of Plasmodium falciparum. Phosphorothioate antisense oligodeoxynucleotides (ODNs) silencing of malarial topoisomerase II gene have shown to possess promising features as anti malarial agents. In order to improve stability and to increase intracellular penetration, ODNs were complexed with the biodegradable polymer chitosan to form solid nanoparticles with an initial diameter of approximately 55 nm. The particle zetapotential depended on the chitosan/ODN mass ratio. Nanoparticles with mass ratio of 2:1 displayed a positive surface charge (+15 mV) whereas particles with 1:1 mass ratio were negatively charged (-20 mV). Additionally nanoparticles were found to protect ODNs from nuclease degradation. P. falciparum K1 strain was exposed to the chitosan/ODN-nanoparticles for 48 h in order to examine the effects of chitosan/antisense (AS) and chitosan/sense (S) oligodeoxynucleotide nanoparticles on malaria parasite growth. Both negatively and positively charged antisense nanoparticles as well as free antisense ODNs (in a final concentration of 0.5 microM) showed sequence specific inhibition compared with sense sequence controls. However, nanoparticles were much more sequence specific in their antisense effect than free ODNs. Nanoparticles with negative surface charge exhibited a significantly stronger inhibitory effect ( approximately 87% inhibition) on the parasite growth in comparison to the positive ones ( approximately 74% inhibition) or free ODNs ( approximately 68% inhibition). This is the first study demonstrating the susceptibility of P. falciparum to antisense nanoparticles.
Föger
Florian
F
Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innrain 52, Josef Möller Haus, A-6020 Innsbruck, Austria.
Noonpakdee
Wilai
W
Loretz
Brigitta
B
Joojuntr
Songwut
S
Salvenmoser
Willi
W
Thaler
Marlene
M
Bernkop-Schnürch
Andreas
A
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology* / Q000627:therapeutic use; D048271:Chitosan / Q000737:chemistry; D004250:DNA Topoisomerases, Type II / Q000187:drug effects* / Q000235:genetics; D003851:Deoxyribonucleases / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism; D006461:Hemolysis; D006801:Humans; D008297:Male; D053758:Nanoparticles; D016376:Oligonucleotides, Antisense / Q000494:pharmacology* / Q000627:therapeutic use; D021261:Parasitic Sensitivity Tests; D010316:Particle Size; D010963:Plasmodium falciparum / Q000187:drug effects / Q000201:enzymology*; D015800:Protozoan Proteins / Q000187:drug effects* / Q000235:genetics; D013499:Surface Properties
D000962:Antimalarials; D016376:Oligonucleotides, Antisense; D015800:Protozoan Proteins; D048271:Chitosan; D003851:Deoxyribonucleases; D004250:DNA Topoisomerases, Type II